Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of mesalazine SPD476 dosing versus placebo in mild to moderate ulcerative colitis
2004-000733-12Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in autoimmune colitis (3 arms), sponsored by Takeda. Primary endpoints: Remission at week 8 and UC-DAI remission assessment. Started Jul 2004; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2004-000733-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000733-12.